ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0027183 | An N-methylated indoleamine derivative and serotonergic hallucinogen which occurs naturally and ubiquitously in several plant species including Psychotria veridis. It also occurs in trace amounts in mammalian brain, blood, and urine, and is known to act as an agonist or antagonist of certain SEROTONIN RECEPTORS. | dmt|N,N-dimethyl-1H-indole-3-ethylamine|3-(2-(Dimethylamino)ethyl)indole|N,-N-dimethyltryptamine|dimethyltryptamine|N,N-dimethyltryptamine|Dimethyltryptamine|DMT|1H-Indole-3-ethanamine, N,N-dimethyl-|2-(3-indolyl)ethyldimethylamine|N,-N-dimethyltryptamine (substance)|dimethyltryptamine (DMT)|N,N Dimethyltryptamine|3-[2-(dimethylamino)ethyl]indole|n, n-Dimethyltryptamine|3-(2-dimethylaminoethyl)indole|N,N-Dimethyltryptamine | N,N-Dimethyltryptamine |
C0887857 | null | Intercistronic Sequence|Sequence, Intercistronic|Sequences, Intergenic|Intercistronic Sequences|Sequences, Intercistronic|Intergenic Sequences|Sequence, Intergenic | Intergenic Sequence |
C0325331 | The sole family in the order Sphenisciformes, comprised of 17 species of penguins in six genera. They are flightless seabirds of the Southern Hemisphere, highly adapted for marine life. | Penguin|Penguin, NOS|penguin|penguins|Family Spheniscidae (organism)|Spheniscidae|Penguins|FAMILY SPHENISCIDAE|Family Spheniscidae | Spheniscidae |
C0042749 | The presence of viruses in the blood. | Viral sepsis|Sepsis, viral|virusemia|Viremia, unspecified|Viremia|viremia|Sepsis caused by virus|viraemia|Viremia, NOS|Sepsis caused by virus (disorder)|Viremia (finding)|Viremias|Viraemia|viral sepsis | Viremia |
C0010674 | An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. | CF - Cystic fibrosis|Fibrosis, Cystic|Mucoviscidosis|pancreas cystic fibrosis|Fibrocystic disease|disease fibrocystic pancreas|disease fibrocystic|cystic fibrosis (CF)|fibrocystic disease|cystic disorder fibrosis|MUCOVISCIDOSIS|Cystic fibrosis|CYSTIC FIBROSIS|CF|mucoviscidosis|Cystic fibrosis NOS|cystic fibrosis|diseases fibrocystic|Cystic fibrosis (disorder)|cystic fibrosis pancreas|fibrocystic disease of pancreas|Cystic Fibrosis | Cystic Fibrosis |
C0023688 | A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) | Ligand|ligands|Ligands|ligand | Ligands |
C0286738 | An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A. | Saquinivir|saquinavir|Saquinavir (substance)|saquinivir|SQV|Saquinavir-containing product|Saquinavir|Product containing saquinavir (medicinal product)|SAQUINAVIR | saquinavir |
C0376637 | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. | Indinavir|Product containing indinavir (medicinal product)|IDV|INDINAVIR|(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide|(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide|Indinavir-containing product|Indinavir (substance)|indinavir|Compound J | indinavir |
C0754188 | A synthetic derivative of hydroxyethylamine sulfonamide that selectively binds to and inhibits human immunodeficiency virus (HIV) protease. | Amprenavir-containing product|amprenavir|Amprenavir|APV|Amprenavirum|(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate|Amprenavir (substance)|Carbamic acid, (3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(- phenylmethyl)propyl)-, tetrahydro-3-furanyl ester, (3S-(3R*(1S*,2R*)))-|tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate|Product containing amprenavir (medicinal product)|Amprénavir|AMPRENAVIR | amprenavir |
C0017890 | A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. | Product containing glycine (medicinal product)|Glycine-containing product|glycine|aminoethanoic acid|Glyzin|Aminoacetic Acid|Glycine (substance)|Glykokoll|Gly|Aminoethanoic acid|Glycin|Glycine - amino acid|Acid, Aminoacetic|Glycocoll|Glycine|Aminoessigsäure|2-aminoacetic acid|Glicina|Aminoacetic acid|GLYCINE|gly | glycine |
C0024337 | An essential amino acid. It is often added to animal feed. | 6-ammonio-L-norleucine|(S)-α,ε-diaminocaproic acid|lysine|L-alpha,epsilon-Diaminocaproic Acid|Lys|Lysinum|Lysine-containing product|LYSINE|L-Lysine|(S)-2,6-Diaminohexanoic acid|LYS|lys|(S)-2,6-diaminohexanoic acid|L-Lysin|(S)-lysine|Lysina|l lysine|l-lysine|Lysine (substance)|L Lysine|L-lysine|Lysine acid|Product containing lysine (medicinal product)|Lysine|L-2,6-Diaminocaproic acid|L-alpha,epsilon-diaminocaproic acid|L-lys | lysine |
C0457406 | null | hinge|Hinge|hinges|Hinge (physical object) | Hinge (physical object) |
C0043843 | null | dipalmitoyl phosphatidylethanolamine|1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine|DHPE|phosphatidylethanolamine dipalmitoate|1,2-dipalmitoyl-3-phosphatidylethanolamine|1,2-dipalmitoyl-rac-glycerophosphoethanolamine|dipalmitoyl cephalin | 1,2-dipalmitoyl-3-phosphatidylethanolamine |
C0037907 | An amino alcohol with a long unsaturated hydrocarbon chain. Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. (Dorland, 28th ed) | 4 Sphingenine|Sphingosine|Sphingosine (substance)|sphingosine|4-Sphingenine|4-Octadecene-1,3-diol, 2-amino-, (R-(R*,S*-(E)))- | Sphingosine |
C0015376 | The leakage of body fluid or cells from the vascular system to the surrounding tissues. This process occurs either by force or as a result of a pathologic reaction (e.g., inflammation). This process may sometimes allow cancer cells to migrate from capillaries to adjacent tissues, initiating micro-metastases. | leakage|Leakage|Spillage, NOS|EXTRAVASATIONS|Leakage, NOS|Extravasation (morphologic abnormality)|extravasation|extravasations|spillages|Extravasation|spillage|Extravasations|Extravasation, NOS|Spillage | Extravasation |
C0242609 | Large multiprotein complexes that bind the centromeres of the chromosomes to the microtubules of the mitotic spindle during metaphase in the cell cycle. | Kinetochore|kinetochore | Kinetochores |
C0034519 | Waves of oscillating electric and MAGNETIC FIELDS which move at right angles to each other and outward from the source. | wave (radiation)|Electromagnetic Radiation|radiation electromagnetic|Energies, Electromagnetic|Electromagnetic Energies|Energy, Electromagnetic|electromagnetic energy|Electromagnetic Waves|Waves, Electromagnetic|Radiation|Radiation, Electromagnetic|Electromagnetic radiation|Electromagnetic Energy|radiation|Electromagnetic radiation (physical force)|Wave, Electromagnetic|Electromagnetic waves|Radiation-Total|EMR|electromagnetic radiations|Electromagnetic Wave|electromagnetism|radiation (unspecified type)|electromagnetic radiation | Electromagnetic Radiation |
C0206416 | Short sequences (generally about 10 base pairs) of DNA that are complementary to sequences of messenger RNA and allow reverse transcriptases to start copying the adjacent sequences of mRNA. Primers are used extensively in genetic and molecular biology techniques. | Oligodeoxyribonucleotide Primers|Primers, Oligodeoxyribonucleotide|DNA primer|Primers, DNA | DNA Primers |
C0297614 | A delayed rectifier subtype of shaker potassium channels that is selectively inhibited by a variety of SCORPION VENOMS. | Potassium Channel, KCNA2|Potassium Channel, Kv1.2|KCNA2 Potassium Channel | Kv1.2 Potassium Channel |
C0037906 | A class of sphingolipids found largely in the brain and other nervous tissue. They contain phosphocholine or phosphoethanolamine as their polar head group so therefore are the only sphingolipids classified as PHOSPHOLIPIDS. | Sphingomyelin|Sphingomyelin (substance)|sphingomyelin | Sphingomyelins |
C0181722 | A branched system of pipes, typically those that attach to an engine to carry away exhaust. | Manifold|manifold | Manifold Device |
C0162862 | null | Arterial Intimas|Intimas, Arterial|Intima, Arterial | Arterial Intima |
C0015352 | Interstitial space between cells, occupied by INTERSTITIAL FLUID as well as amorphous and fibrous substances. For organisms with a CELL WALL, the extracellular space includes everything outside of the CELL MEMBRANE including the PERIPLASM and the cell wall. | extracellular space|Space, Extracellular|Spaces, Intercellular|Intercellular space, NOS|Space, Intercellular|Extracellular space, NOS|Extracellular Space|Extracellular Spaces|Extracellular space (body structure)|Intercellular Space|intercellular space|Extracellular space|Spaces, Extracellular|Intercellular space|Intercellular space (body structure)|Intercellular Spaces | Extracellular Space |
C0991566 | A solid in the shape of a small sphere. | Beads|beaded|bead|BEAD|Bead Dose Form|Bead Dosage Form|beads|beading|Bead | Bead Dosage Form |
C0051066 | A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called antimetabolites. | L-2-Amino-3-[(N-nitroso)hydroxylamino]propionic acid|L-2-amino-3-(hydroxynitrosoamino)propionic acid|3-(Hydroxynitrosoamino)-L-alanine|ALANOSINE|L-Alanosine|L-Alanosine Sodium|L-2-amino-3-(N-nitroso)hydroxylaminopropionic acid|L-alanosine|L-2-Amino-3-(hydroxynitrosoamino)propionic Acid|L-2-Amino-3-[(N-nitroso)hydroxylamino]propionic Acid|l-alanosine|3-(hydroxynitrosoamino)-L-alanine|L-2-amino-3-[(N-nitroso)hydroxylamino]propionic acid|Alanosine|L-alanosine sodium|Alanosina|Alanosinum|alanosine | alanosine |
C0035495 | Spherical phototrophic bacteria found in mud and stagnant water exposed to light. | Rhodopseudomonas sphaeroides|Rhodobacter sphaeroides|Rhodorhagus minor|Rhodorrhagus spheroides|Rhodobacter sphaeroides (organism)|Rhodopseudomonas spheroides|Rhodobacter spheroides|Rhodococcus minor|Rhodosphaera capsulata|Rhodococcus capsulatus|Rhodorrhagus capsulatus|Rhodosphaera minor|Rhodorhagus capsulatus | Rhodobacter sphaeroides |
C0040682 | changes of a cell that effects its morphology and physiology through natural or artificial mechanisms or sources; typically pathologic; do not confuse with CELL DIFFERENTIATION. | transformation|cell transformation|Cell transformation|transformation cell|transformations | cell transformation |
C0086486 | The weighted concentration of ions in solutions. | Strength, Ionic|Ionic Strengths|Ionic Strength|Strengths, Ionic|ionic strength | Ionic Strength |
C0036140 | Substances produced from the reaction between acids and bases; compounds consisting of a metal (positive) and nonmetal (negative) radical. (Grant & Hackh's Chemical Dictionary, 5th ed) | salt|Salts|salts|Salt | Salts |
C0002726 | A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits. | Amyloidosis NOS|amyloidoses|amyloid diseases|Amyloidosis (disorder)|amyloid disease|Amyloidoses|Amyloidosis, NOS|AMYLOIDOSIS|Amyloidosis, unspecified|Amyloid disease|AMYLOID|amyloidosis|Amyloidosis | Amyloidosis |
C0020268 | The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. | Hydrocortisone preparation|hydrocortisone|cortisols|Cortisol preparation|Hydrocortisone (substance)|11beta-hydrocortisone|HYDROCORTISONE|Hydrocortisone|Hydrocortisone-containing product|therapeutic hydrocortisone|4-pregnen-11β,17α,21-triol-3,20-dione|(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione|17-hydroxycorticosterone|HC|Hydrocortisonum|Product containing hydrocortisone (medicinal product)|(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione|hydrocortisones|cortisol|Compound F preparation|Hidrocortisona|Compound F|17-Hydroxycorticosterone|11β-hydrocortisone|Cortisol|Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-|Therapeutic Hydrocortisone|11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione|Domolene | hydrocortisone |
C1269683 | Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5) | Major depressive disorder|Major depression|Major depressive disorder, NOS|MAJOR DEPRESSIVE DISORDER|MDD|Depressive Disorder, Major|Major depressive disorder (disorder)|major depressive illness|major depressive disorder|Major Depressive Disorders|major depression|Major Depressive Disorder|Major depression, NOS|MAJOR DEPRESSION|Depressive Disorders, Major | Major Depressive Disorder |
C0442004 | null | Septal (qualifier value)|septal | Septal |
C0175232 | null | Nucleus Lateralis Septus|Lateral Septum Nucleus|Lateral septal nucleus|Nucleus, Lateral Septum|Nucleus Septalis Laterali|Nucleus Septi Laterali|Laterali, Nucleus Septi|Septalis Laterali, Nucleus|Lateralis Septi, Nucleus|Nucleus Lateralis Septi|Laterali, Nucleus Septalis|Septi Lateralis, Nucleus|Lateral Septal Nucleus|Lateralis Septus, Nucleus|Lateralis, Nucleus Septalis|Lateral parolfactory nucleus|Lateralis, Nucleus Septi|Septalis Lateralis, Nucleus|Septal Nucleus, Lateral|Septi Laterali, Nucleus|Nucleus septalis lateralis|Nucleus lateralis septi|Septi, Nucleus Lateralis|Nucleus Septi Lateralis|Nucleus, Lateral Septal|Septus, Nucleus Lateralis|Septum Nucleus, Lateral|Nucleus Septalis Lateralis | Lateral Septal Nucleus |
C0031890 | A noncompetitive antagonist at GABA-A receptors and thus a convulsant. Picrotoxin blocks the GAMMA-AMINOBUTYRIC ACID-activated chloride ionophore. Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. | Picrotoxin|picrotoxins|picrotoxin|Picrotoxin (substance)|3,6-Methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8aS*,8bbeta,9S*))-, compd. with (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8aS*,8bbeta,9R*))-hexahydro-2a-hydroxy-8b-methyl-9-(1-methylethenyl)-3,6-methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione (1:1) | Picrotoxin |
C0070122 | A serotonin uptake inhibitor that is effective in the treatment of depression. | Paroxetinum|Paroxetine|PAROXETINE|(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine|Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S-trans)-|(-)-trans-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine|(3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine|PARoxetine|Paroxetina|Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3s-trans)-|Paroxetine-containing product|paroxetine|Paroxetine (substance)|Product containing paroxetine (medicinal product)|(-)-(3S,4R)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine | paroxetine |
C0080073 | null | quisqualate | Quisqualate |
C0175392 | The dorsal region of the raphe nucleus which is a source of the SEROTONERGIC NEURONS innervating the TELENCEPHALON; DIENCEPHALON; MESENCEPHALON; and RHOMBENCEPHALON. | DRN|Dorsal Raphe|Dorsal nucleus raphe|Nucleus dorsalis raphes|Dorsal Nucleus Raphe|Nucleus Raphes Dorsali|Nucleus Raphes Dorsalis|dorsal raphe nucleus|Nucleus, Dorsal Raphe|Dorsal Raphe Nucleus|drn|Dorsal Nucleus Of The Raphe|Raphes Dorsalis, Nucleus|Dorsal nucleus of the raphe|Nucleus Raphe Dorsali|Raphe Dorsali, Nucleus|Posterior raphe nucleus|Dorsal Raphes|Dorsal raphe nucleus|Dorsalis, Nucleus Raphe|Nucleus Raphe, Dorsal|Nucleus Raphe Dorsalis|Nucleus raphes posterior|Dorsali, Nucleus Raphes|Raphe Dorsalis, Nucleus|Raphes Dorsali, Nucleus|Cell group B7|Raphe, Dorsal Nucleus|Nucleus raphe dorsalis|Dorsalis, Nucleus Raphes|brain dorsal raphe nucleus (DRN)|nucleus raphe dorsalis|Dorsali, Nucleus Raphe|Raphe, Dorsal|Nucleus raphes dorsalis | dorsal raphe nucleus |
C0270549 | A condition marked by excessive worry and feelings of fear, dread, and uneasiness that last six months or longer. Other symptoms of GAD include being restless, being tired or irritable, muscle tension, not being able to concentrate or sleep well, shortness of breath, fast heartbeat, sweating, and dizziness. | Generalized anxiety disorder|GAD - Generalized anxiety disorder|Generalized Anxiety Disorder|anxiety disorders generalized|generalised anxiety disorder|gads|gad|GENERALIZED ANXIETY DISORDER|generalized anxiety disorder|anxiety disorder generalized|Generalised anxiety disorder|anxiety disorder generalize|GAD - Generalised anxiety disorder|GAD|Generalized anxiety disorder (disorder)|generalized anxiety disorders | Generalized Anxiety Disorder |
C0015726 | The affective response to an actual current external danger which subsides with the elimination of the threatening condition. | Fearfulness|frightened|afraid|fright|frightening|Afraid|fear symptoms|scares|Fears|Fear|scaring|fear of|focused anxiety|Fear (finding)|fearing|scared|Frightened|symptoms fear|scare, scared|Fear (specify)|fear|scare|fears|Fearful|Fear of|Scared|Fright | Fear (Mental Process) |
C0003469 | Persistent and disabling ANXIETY. | anxiety disorder|Anxiety disorder|Anxiety disorder, NOS|Anxiety Disorders|anxiety|Disorders, Anxiety|anxiety disorder nos|Anxiety|Anxiety disorder (disorder)|anxiety disorders|Disorder, Anxiety|Anxiety disorders|Anxiety Disorder|ANXIETY DISORDERS | Anxiety Disorders |
C0026447 | Any haplorhine primate not belonging to the family Tarsiidae, Hylobatidae, Pongidae, or Hominidae; this does not correspond to any taxon. This group is divided into Old World monkeys (Cercopithecidae) and New World monkeys (Callitrichidae and Cebidae). Many types are used as an experimental model for human disease and drug testing. | monkeys|Monkey|MONKEY|Monkey, NOS|Monkey (organism)|Monkeys|monkey | Monkeys |
C0258459 | null | SR141716A|SR-141716A | SR 141716A |
C0378126 | A subclass of cannabinoid receptor found primarily on central and peripheral NEURONS where it may play a role modulating NEUROTRANSMITTER release. | Receptor CB1, Cannabinoid|Receptor, CB1|CB1 Receptor|Cannabinoid Receptor CB1|Receptor, Cannabinoid, CB1 | Receptor, Cannabinoid, CB1 |
C1123034 | null | Guaranas|Guarana|cupana, Paullinia|Paullinia cupanas|Paullinia cupana|guarana|paullinia cupana | Guarana |
C1280903 | An observation of the body or a body part done by inspection and/or palpation | Exploration - action|exploration|Exploration|Exploration - action (qualifier value)|Exploration procedure (procedure) | Exploration procedure |
C0002199 | One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. | Interferon alpha|Product containing interferon alfa (medicinal product)|HuIFN-alpha-Le|Interferon Alfa|leukocyte interferon|Interferon, Lymphoblastoid|Interferon alfa (substance)|Interferon alfa-containing product|alpha Interferon|Interferon, alpha|Lymphoblastoid Interferon|interferon-alpha|IFN-α|IFNa|alpha-Interferon|Interferon alfa|alpha interferon|Interferon, Lymphoblast|Leukocyte Interferon|alpha interferons|alpha-interferon|Lymphoblast Interferon|Natural alpha interferon|Alpha interferon|Interferon-alpha|interferon alfa|interferon alpha|interferon alfa natural|Interferon, Leukocyte | Interferon-alpha |
C0021747 | Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. | Product containing interferon (product)|Interferon|interferons|Interferons|Interferon-containing product|interferon|Interferon (substance)|INTERFERON|IFN | Interferons |
C0733439 | null | null | Chloridin |
C0733439 | null | null | Chloridin |
C0733439 | null | null | Chloridin |
C0733439 | null | null | Chloridin |
C0025810 | A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE. | methyl α-phenyl-α-(2-piperidyl)acetate|Methylphenidate|Methylphenidate (substance)|d-methylphenidate|Methylphenidan|METHYLPHENIDATE|2-Piperidineacetic acid, alpha-phenyl-, methyl ester|Methylphenidate-containing product|Methyl phenidylacetate|alpha-Phenyl-2-piperidineacetic Acid Methyl Ester|Methylphenidatum|Metilfenidato|Product containing methylphenidate (medicinal product)|α-phenyl-2-piperidineacetic acid methyl ester|methyl phenyl(piperidin-2-yl)acetate|methylphenidate|MPH|methyl α-phenyl-α-2-piperidinylacetate | methylphenidate |
C0015215 | The electric response evoked in the CEREBRAL CORTEX by ACOUSTIC STIMULATION or stimulation of the AUDITORY PATHWAYS. | evoked auditory response|Auditory evoked response|Auditory evoked potential, function (observable entity)|Auditory Evoked Potentials|AER - Auditory evoked responses|Auditory evoked potential, function|Auditory evoked potential|Evoked Response, Auditory|auditory evoked response|AEP - Auditory evoked potentials|Auditory Evoked Potential|Auditory Evoked Responses|Auditory evoked potentials|Auditory Evoked Response|Potentials, Auditory Evoked|auditory evoked potentials|auditory evoked potential|Evoked Potentials, Auditory|Evoked Responses, Auditory|Evoked Potential, Auditory|auditory evoked responses | Auditory Evoked Potentials |
C0016293 | A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses. | Flumazepil|flumazepil|4H-Imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylic acid, 8-fluoro-5,6-dihydro-5-methyl-6-oxo-, ethyl ester|Flumazenilo|flumazenil|Flumazenil|Flumazenilum|4H-Imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylic Acid, 8-fluoro-5,6-dihydro-5-methyl-6-oxo-, Ethyl Ester|FLUMAZENIL|Flumazenil-containing product|Flumazenil (substance)|Product containing flumazenil (medicinal product) | flumazenil |
C0012010 | A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity. | diazepam|7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one|Product containing diazepam (medicinal product)|DIAZEPAM|Diazepam|7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one|Methyl diazepinone|2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-|Diazepam (substance)|Diazepam-containing product | diazepam |
C0753114 | A ubiquitously expressed G-protein-coupled receptor kinase subtype that has specificity for the agonist-occupied form of BETA-ADRENERGIC RECEPTORS. It may play an essential role in regulating myocardial contractile response. | BETA-ARK1|ADRBK1|G Protein Coupled Receptor Kinase 2|beta Adrenergic Receptor Kinase 1|BARK1|G-Protein Coupled Receptor Kinase 2|beta-Adrenergic Receptor Kinase 1|G Protein-Dependent Receptor Kinase 2|EC 2.7.1.126|G-Protein-Coupled Receptor Kinase 2|Adrenergic Beta Receptor Kinase 1|GRK2|Beta-Adrenergic Receptor Kinase 1|EC 2.7.11.15|Beta-ARK-1 | Beta-Adrenergic Receptor Kinase 1 |
C0540641 | null | Adrenergic Receptor alpha-2b|alpha-2B Receptors, Adrenergic|Receptors, Adrenergic, alpha-2B|Receptor, Adrenergic, alpha-2B|Adrenergic Receptor, alpha-2B|Receptor alpha-2b, Adrenergic|Adrenergic Receptor alpha 2b|alpha-2B Adrenergic Receptor|Receptors, Adrenergic alpha-2B|alpha 2B Adrenergic Receptor|Adrenergic alpha-2B Receptors|Adrenergic alpha 2B Receptors|alpha-2b, Adrenergic Receptor|Receptor, alpha-2B Adrenergic | adrenergic receptor alpha-2b |
C0285499 | A ubiquitously expressed G-protein-coupled receptor kinase subtype that has specificity for the agonist-occupied form of BETA-ADRENERGIC RECEPTORS and a variety of other G-PROTEIN-COUPLED RECEPTORS. Although it is highly homologous to G-PROTEIN-COUPLED RECEPTOR KINASE 2, it is not considered to play an essential role in regulating myocardial contractile response. | beta Adrenergic Receptor Kinase 2|Beta-Adrenergic Receptor Kinase 2|GRK3|Beta Adrenergic Receptor Kinase 2|BARK2|G-Protein Coupled Receptor Kinase 3|EC 2.7.1.126|Beta-ARK-2|ADRBK2|EC 2.7.11.15|G-Protein-Coupled Receptor Kinase 3|G Protein Coupled Receptor Kinase 3|beta-Adrenergic Receptor Kinase 2 | Beta-Adrenergic Receptor Kinase 2 |
C0166470 | null | L-aspartic acid, L-alanyl-L-valyl-L-glutaminyl-L-seryl-L-lysyl-L-prolyl-L-prolyl-L-seryl-L-lysyl-L-arginyl-L-alpha-aspartyl-L-prolyl-L-prolyl-L-lysyl-L-methionyl-L-glutaminyl-L-threonyl- | systemin |
C0123931 | The active ingredient in a drug used alone or with other drugs to treat colon cancer or rectal cancer that has spread to other parts of the body or has come back after treatment with fluorouracil. It is also being studied in the treatment of other types of cancer. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog. | (+)-(4S)-4,11-diethyl-4-hydroxy-9-[(4-piperidino-piperidino)carbonyloxy]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-3,14,(4H,12H)-dione|Irinotecan (substance)|IRINOTECAN|(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate|Irinotecanum|Product containing irinotecan (medicinal product)|7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin|(+)-Irinotecan|irinotecan|[1,4'-bipiperidine]-1'-carboxylic acid (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester|Irinotecan-containing product|Irrinotecan|Irinotecan|(1,4'-Bipiperidine)-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester|Irinotecan lactone | irinotecan |
C1518418 | Dedicated to the development and conduct of innovative clinical trials that will ultimately result in a cure for patients with malignant brain tumors. Their goals are 1) to discover new and effective therapies for the treatment of patients with brain tumors, including anti-angiogenesis drugs, differentiating agents, anti-invasive medications, and new molecular agents such as gene therapy; 2) to develop innovative combination strategies to enhance the therapeutic effects of chemotherapy and radiation treatments; and 3) to develop and fund translational research opportunities that will bring exciting new agents and strategies from the laboratory to the clinical setting. | NABTC | North American Brain Tumor Consortium |
C0555198 | A grade III or grade IV glioma arising from the central nervous system. This category includes glioblastoma, anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma. | Malignant Neuroglial Neoplasm|High-Grade Glioma|Malignant Glial Neoplasm|Malignant Glioma|malignant glioma|Glioma, malignant, no ICD-O subtype|GLIOMA, MALIGNANT|Glioma, malignant (morphologic abnormality)|High Grade Glioma|Glioma, malignant|Malignant Neuroglial Tumor|Malignant glioma - category|malignant gliomas|Malignant Gliomas|Glioma (except Nasal glioma, not neoplastic)|Malignant Glial Tumor|Glioma, NOS (except Nasal glioma, not neoplastic)|Malignant glioma - category (morphologic abnormality)|Glioma, Malignant|Gliomas, Malignant|Malignant glioma | Malignant Glioma |
C0017636 | A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. | Grade IV Astrocytic Neoplasm|ASTROCYTOMA, GRADES 3-4|GBM (Glioblastoma)|WHO Grade IV Glioma|GBM|Glioblastoma, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|grade IV astrocytoma|Glioblastoma multiforme|glioblastomas|Glioblastoma|Glioblastoma, NOS|Astrocytomas, Grade IV|Grade IV Astrocytoma|Astrocytoma, Grade IV|Glioblastoma, no International Classification of Diseases for Oncology subtype|Grade IV Astrocytomas|Grade IV Astrocytic Tumor|glioblastoma|Glioblastoma, Not Otherwise Specified|Glioblastoma, no ICD-O subtype|Glioblastomas|grade iv astrocytoma | Glioblastoma |
C0235029 | null | complications neurologic|complications neurological|neurologic complication|Nervous system complication, unspecified|NEUROLOGIC COMPLICATION | neurological complication |
C0521401 | null | leptomeningeal|Leptomeningeal | Leptomeningeal |
C0034155 | An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases. | Moschcowitz's syndrome|thrombotic thrombocytopenic purpura|T.T.P. syndrome|PURPURA THROMBOPENIC THROMBOTIC|Moschcowitz syndrome|Moschkowitz Disease|TTP - Thrombotic thrombocytopenic purpura|PURPURA, THROMBOCYTOPENIC, THROMBOTIC|Thrombopenic Purpura, Thrombotic|THROMBOTIC THROMBOCYTOPENIC PURPURA|Thrombotic Thrombopenic Purpura|MOSCHCOWITZ SYNDROME|Thrombotic Thrombocytopenic Purpura|Thrombotic thrombocytopenic purpura|Thrombocytopenic Purpura, Thrombotic|TTP|Moschowitz's syndrome|PURPURA, THROMBOHEMOLYTIC|Thrombotic-thrombocytopenic purpura|thrombotic thrombopenic purpura|moschcowitz's syndrome|Moschcowitz Disease|Moschowitz disease|Purpura, Thrombotic Thrombocytopenic|ttp|thrombotic thrombocytopenic purpura (TTP)|Thrombotic thrombocytopenic purpura (disorder)|Purpura, Thrombotic Thrombopenic|Moschowitz Disease | Purpura, Thrombotic Thrombocytopenic |
C0333209 | null | Thrombus, platelet|Platelet thrombus|Platelet thrombus (morphologic abnormality) | Platelet thrombus |
C0001511 | A fibrous band of tissue that connects normally separate body regions. | Adhesion, Tissue|Tissue Adhesions|ADHESION|adhesions|Adhesion (morphologic abnormality)|Adhesion(s)|Adhesion|abnormal attachment of organs or body parts|adhesion|Adhesions, Tissue|Adhesions|Tissue Adhesion|Adhesion, NOS | Tissue Adhesions |
C0022688 | Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. | Killer Cells, Natural|killer cell|NK Cells|Natural Killer Cells|nk cell|cells natural killer|NK|Cell, Natural Killer|nk cells|K cell|natural killer cells|Cell, NK|K lymphocyte|Natural killer cell (cell)|natural killer cell|nk-cell|Natural killer cell|Cells, NK|NK-Cell|NK cell|Natural killer (NK)-cell|Killer cell|Killer Cell, Natural|NK Cell|Killer Cells|Natural Killer Cell|Killer Cell|NK-LGL|Cells, Natural Killer|NK-cell | Natural Killer Cells |
C1167622 | The selective, non-covalent, often stoichiometric, interaction of a molecule with one or more specific sites on another molecule. [GOC:ceb, GOC:mah, ISBN:0198506732] | Molecular Interaction|Molecular Interaction Process|Physical Interaction|Binding|molecular interaction|bind|binds|binding [molecular function]|binding | Binding (Molecular Function) |
C0017376 | The functional hereditary units of VIRUSES. | Viral Genes|Viral gene|Gene, Viral|Viral gene (substance)|Viral Gene | Genes, Viral |
C0017399 | Used for mechanisms of heredity and the genetics of organisms, for the genetic basis of normal and pathologic states, and for the genetic aspects of endogenous chemicals. It includes biochemical and molecular influence on genetic material. | genetics | genetic aspects |
C0027803 | An enzyme that catalyzes the hydrolysis of alpha-2,3, alpha-2,6-, and alpha-2,8-glycosidic linkages (at a decreasing rate, respectively) of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid, and synthetic substrate. (From Enzyme Nomenclature, 1992) | NEURAMININASE (SIALIDASE)|Neuraminidase|sialidase|Exo-alpha-Sialidase|neuraminidase|N Acylneuraminate Glycohydrolases|exo alpha sialidase|Sialidase|Sialidase, Oligosaccharide|Exo alpha Sialidase|Glycohydrolases, N-Acylneuraminate|Sialidase (substance)|Acylneuraminyl hydrolase|N-Acylneuraminate Glycohydrolases|Oligosaccharide Sialidase | Neuraminidase |
C0003451 | Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. | Antiviral agent|Antiviral Drugs|Agents, Antiviral|Antiviral Agents|antiviral|antiviral drugs|Substance with antiviral mechanism of action (substance)|Antiviral-containing product|Substance with antiviral mechanism of action|Antiviral Agent [TC]|Antiviral Agent|Antiviral drug|antiviral drug|Product containing antiviral (product)|Antivirals|Medicinal product acting as antiviral (product)|Antiviral agent, NOS|ANTIVIRALS|antivirals|Antiviral agents|Drugs, Antiviral|antiviral agent|antiviral agents|ANTIVIRAL AGENTS|Antiviral | Antiviral Agents |
C1155229 | An immune response mediated through a body fluid. [GOC:hb, ISBN:0198506732] | adaptive immune responses|Immune Responses, Humoral|humoral immune response|Humoral Immune Responses|Response, Humoral Immune|Immune Response, Humoral|Humoral Immune Response | Humoral immune response |
C0012161 | A diet that contributes to the development and acceleration of ATHEROGENESIS. | atherogenic diet|Atherogenic Diet|Atherogenic Diets|Diets, Atherogenic | Diet, Atherogenic |
C0012161 | A diet that contributes to the development and acceleration of ATHEROGENESIS. | atherogenic diet|Atherogenic Diet|Atherogenic Diets|Diets, Atherogenic | Diet, Atherogenic |
C0015525 | Stable blood coagulation factor activated by contact with the subendothelial surface of an injured vessel. Along with prekallikrein, it serves as the contact factor that initiates the intrinsic pathway of blood coagulation. Kallikrein activates factor XII to XIIa. Deficiency of factor XII, also called the Hageman trait, leads to increased incidence of thromboembolic disease. Mutations in the gene for factor XII that appear to increase factor XII amidolytic activity are associated with HEREDITARY ANGIOEDEMA TYPE III. | factor xii|Hageman Factor|Hageman factor|Factor XII|coagulation factor XII|Coagulation Factor XII|Coagulation factor XII|factor hageman|Coagulation factor XII (substance)|Factor 12|Factor Twelve|hageman factor|Blood-coagulation factor XII | Factor XII |
C0015525 | Stable blood coagulation factor activated by contact with the subendothelial surface of an injured vessel. Along with prekallikrein, it serves as the contact factor that initiates the intrinsic pathway of blood coagulation. Kallikrein activates factor XII to XIIa. Deficiency of factor XII, also called the Hageman trait, leads to increased incidence of thromboembolic disease. Mutations in the gene for factor XII that appear to increase factor XII amidolytic activity are associated with HEREDITARY ANGIOEDEMA TYPE III. | factor xii|Hageman Factor|Hageman factor|Factor XII|coagulation factor XII|Coagulation Factor XII|Coagulation factor XII|factor hageman|Coagulation factor XII (substance)|Factor 12|Factor Twelve|hageman factor|Blood-coagulation factor XII | Factor XII |
C0055959 | null | null | clotting enzyme |
C0377993 | A subgroup of cyclic nucleotide-regulated ION CHANNELS within the superfamily of pore-loop cation channels. They are expressed in OLFACTORY NERVE cilia and in PHOTORECEPTOR CELLS and some PLANTS. | Cyclic Nucleotide Gated Cation Channels|Gated Channel, Cyclic-Nucleotide|Cyclic Nucleotide Gated Ion Channels|Cyclic-Nucleotide Gated Ion Channels|Cyclic-Nucleotide Gated Channel|Cyclic Nucleotide Gated Channel|Channel, Cyclic-Nucleotide Gated | Cyclic Nucleotide-Gated Cation Channels |
C0079870 | Genetically engineered MUTAGENESIS at a specific site in the DNA molecule that introduces a base substitution, or an insertion or deletion. | Targeted Modification|Mutageneses, Site-Specific|Mutagenesis, Site Directed|Site Specific Mutagenesis|Mutagenesis, Site Specific|Targeted Mutation|Site-Specific Mutageneses|site directed mutagenesis|Targeted DNA Modification|Site-specific mutagenesis|Site Directed Mutagenesis|Mutageneses, Site-Directed|directed mutagenesis site|site-directed mutagenesis|Targeted DNA Alteration|Targeted Sequence Alteration|Site-Directed Mutageneses|Mutagenesis, Site-Specific|Site-Specific Mutagenesis|Site-Directed Mutagenesis | Mutagenesis, Site-Directed |
C0021400 | An acute viral infection of the respiratory tract, occurring in isolated cases, in epidemics, or in pandemics; it is caused by serologically different strains of viruses (influenzaviruses) designated A, B, and C, has a 3-day incubation period, and usually lasts for 3 to 10 days. It is marked by inflammation of the nasal mucosa, pharynx, and conjunctiva; headache; myalgia; often fever, chills, and prostration; and occasionally involvement of the myocardium or central nervous system. | influenzas|flu|Influenza|Influenza in Human|flus|Human Flu|Influenza, NOS|INFLUENZA|influenza|Influenzas|GRIP|Influenza (disorder)|grippe|Influenza, Human|Flu|FLU|SYNDROME FLU|Human Influenza|Human Influenzas|Influenzas, Human|Grippe|Flu, Human|Influenza NOS|Influenza in Humans|FLU SYNDROME|flu syndrome | Influenza |
C0007448 | Positively charged atoms, radicals or groups of atoms with a valence of plus 2, which travel to the cathode or negative pole during electrolysis. | Divalent Cations|divalent cation | Cations, Divalent |
C0178708 | null | null | immortalized cell |
C0053932 | Bone-growth regulatory factors that are members of the transforming growth factor-beta superfamily of proteins. They are synthesized as large precursor molecules which are cleaved by proteolytic enzymes. The active form can consist of a dimer of two identical proteins or a heterodimer of two related bone morphogenetic proteins. | bmp|Bone Morphogenetic Proteins|bone morphogenetic protein|Bone Morphogenetic Protein Family|BMP|bone morphogenetic proteins|Bone Morphogenetic Protein|Morphogenetic Proteins, Bone|Bone morphogenetic proteins|Morphogenetic Protein, Bone|BMP Family | Bone Morphogenetic Proteins |
C0282524 | The most common of the microsatellite tandem repeats (MICROSATELLITE REPEATS) dispersed in the euchromatic arms of chromosomes. They consist of two nucleotides repeated in tandem; guanine and thymine, (GT)n, is the most frequently seen. | Dinucleotide Repeat | Dinucleotide Repeats |
C0162789 | A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei. | Fluorescent in Situ Hybridization|FISH (fluorescent in situ hybridization)|fluorescence in situ hybridization (FISH)|fishing techniques|fluorescence hybridization situ|FISH - fluorescence in situ hybridization|Technic, FISH|Techniques, FISH|Fluorescence in situ hybridization (procedure)|Hybridization in Situ, Fluorescence|fish technique|FISH - fluorescence in situ hybridisation|FISH Techniques|FISH Technics|Technique, FISH|fluorescent hybridization situ|Fluorescence in situ hybridization|FISH Technique|Technics, FISH|Fluorescence in situ hybridisation|Hybridization in Situ, Fluorescent|FISH|In Situ Hybridization, Fluorescent|Fluorescence in Situ Hybridization|Fluorescence In Situ Hybridization|FISH Technic|In Situ Hybridization, Fluorescence|fluorescent in situ hybridization|Fluorescence in situ Hybridization|fluorescence in situ hybridization | Fluorescent in Situ Hybridization |
C0086222 | A 50-150bp DNA sequence that increases the rate of transcription of coding sequences. It may be located at various distances and in either orientation upstream from, downstream from or within a structural gene. When bound by a specific transcription factor it increases the levels of expression of the gene, but is not sufficient alone to cause expression. Distinguished from a promoter, that is alone sufficient to cause expression of the gene when bound. | enhancer of transcription|enhancer of DNA transcription|enhancer of transcription [DNA]|Enhancer | Enhancer of transcription |
C0599561 | null | E protein | e protein |
C0232338 | null | Blood flow, NOS|blood flowing|Blood Flow|Blood flow|blood flow|VASCULAR FLOW|blood flow function|blood flows|Vascular flow, function|Vascular Flow|Vascular flow, NOS|Vascular flow, function (observable entity)|Vascular flow | Blood flow |
C0033613 | Synthetic or natural substances which are given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent. | Protective agent|protectants|Protective Drugs|Drugs, Protective|Protective Agents|Protective Agent|Protective drug, NOS|Protective agent (product)|Protective drug|protective drugs|Protectant, NOS|Protective Drug|protectant|PROTECTIVE AGENTS|Agents, Protective | Protective Agents |
C0020746 | The solid substance formed by the FREEZING of water. | Ice|ice|Ice (substance)|Water Ice|Frozen Water | Ice |
C0036208 | The excitable plasma membrane of a muscle cell. (Glick, Glossary of Biochemistry and Molecular Biology, 1990) | Plasma membrane of muscle cell|sarcolemma|Sarcolemma structure|Sarcolemma|Sarcolemma structure (cell structure)|Sarcolemmas | Sarcolemma |
C0031667 | Phospholipases that hydrolyze the acyl group attached to the 2-position of PHOSPHOGLYCERIDES. | phospholipase A2|Lecithinase A|lecithinase A|Phospholipase A2|phosphatidase|Lecithinase A2|phosphatidolipase|Phospholipase A>2< (substance)|Phospholipase A>2<|PLA2|phospholipase a2|Phosphatidolipase|Phosphatidase|Phospholipase A2 (substance)|Phospholipase A<sub>2</sub>|phospholipase a 2|EC 3.1.1.4|Phospholipase A2 Enzyme Family|Phospholipases A2|Phospholipase A<sub>2</sub> (substance)|phosphatidylcholine 2 acylhydrolase | Phospholipases A2 |
C0004391 | The cellular catabolic process in which cells digest parts of their own cytoplasm; allows for both recycling of macromolecular constituents under conditions of cellular stress and remodeling the intracellular structure for cell differentiation. [GOC:autophagy, ISBN:0198547684, PMID:11099404, PMID:9412464] | Cellular Autophagy|Autophagocytosis|Autophagy|autophagy|autophagy/autophagia|Autophagy, Cellular | Autophagy |
C0182537 | A device designed to facilitate the movement of a fluid. | pumping|Pump Device|Pump, device|Pump, device (physical object)|pump|Pump|Pump, NOS|pumped|pumps | pump (device) |
C0184967 | null | Packing|Packing procedure|Insertion of pack (procedure)|packed|Packed|packing|Insertion of pack | Insertion of pack (procedure) |
C0028944 | A class of large neuroglial (macroglial) cells in the central nervous system. Oligodendroglia may be called interfascicular, perivascular, or perineuronal (not the same as SATELLITE CELLS, PERINEURONAL of GANGLIA) according to their location. They form the insulating MYELIN SHEATH of axons in the central nervous system. | Oligodendrocytes|Oligodendroglia cell|Oligodendrocyte|Oligodendroglia|oligodendrocyte|Oligodendrocytus|Oligodendroglia Cell|oligodendrocytes|Oligodendrocyte (cell)|oligodendroglia|Oligodendroglial cell|cells oligodendrocytes | Oligodendroglia |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.